OBJECTIVE The study evaluated the effectiveness of Ketamine Intravenous Therapy (KIT) in reducing post-traumatic stress disorder (PTSD) and depression symptoms, using electronic health record data from outpatient psychiatric patients with PTSD. METHOD We analyzed data from 8,136 patients diagnosed with PTSD, 87 % (N = 7,070) of whom also had comorbid depression. Symptom severity was measured...
Depression is a prevalent and heterogeneous disorder with significant personal and social consequences. The rise of treatment-resistant depression (TRD) challenges traditional approaches and underscores the need for a broader neurobiological perspective. When monoaminergic modulation proves insufficient, clinical guidelines increasingly turn to non-monoaminergic interventions such as...
Antidepressant effects with sub-anesthetic doses of intravenous ketamine have been previously demonstrated. However, previous studies have primarily evaluated the efficacy of acute treatment protocols, with limited research on maintenance treatment. Moreover, controlled maintenance studies have only included patients with treatment-resistant Major Depressive Disorder (TRD), with no maintenance...
Ketamine and its enantiomers, esketamine and arketamine, have emerged as promising treatments for treatment-resistant depression (TRD). This cross-sectional study evaluates the regulatory alignment of 40 clinical trials listed on ClinicalTrials.gov, focusing on the methodological challenges. The study highlights methodological inconsistencies, particularly around the challenges of functional...
INTRODUCTION Anhedonia, defined as the diminished ability to experience or anticipate pleasure, is a core symptom of major depressive disorder (MDD) and bipolar depression (BD), and associated with depression severity, suicidality and poor treatment outcomes. Conventional antidepressants demonstrate limited efficacy against anhedonia. Esketamine nasal spray (ESK-NS) - a novel NMDA receptor...
Psychiatry ResearchJuly 19, 2025Kevin J Li, Natalie E Slama, Ingrid L Chen et al.2 citations
Interventional psychiatric procedures (IPPs) such as electroconvulsive therapy (ECT), transcranial magnetic stimulation (TMS), and ketamine intravenous treatments (KIT) are widely used for treatment resistant depression (TRD), but we lack studies of their real-world impact compared to standard outpatient medication management (MM). Longitudinal electronic health records of 22,481 patients in a...
The brain mechanisms underlying patient improvement after interventions remain poorly understood. Identifying the shared and distinct neural pathway between improvement mechanisms across distinct treatment modalities might improve our understanding of brain-behavior relationships and inform personalized approaches. To investigate the neural correlations of symptom improvement in Generalized...
This study evaluated the effects of Mindfulness-based stress reduction(MBSR) and cognitive behavioural stress reduction(CBSR) on depression, anxiety, and perceived stress in medical students. A total of 323 medical students studying in Ankara, Turkey, applied to participate and were assessed using the Mini International Neuropsychiatric Interview. Medical students with a psychotic disorder,...
LSD (lysergic Acid Diethylamide), a psychedelic compound, has been investigated in recent studies for the treatment of mental disorders. We analyzed the efficacy and safety of LSD in the treatment of mental disorders and substance use disorders in adult patients. We searched Embase, PubMed, Scopus, PsycINFO, the Cochrane Library, CENTRAL, BVS, EBSCO, Epistemonikos, and the grey literature for...
Psychiatry ResearchJuly 1, 2025Mazyar Fathi, Mohammad Navid Ebrahimi, Mohammad Banazadeh et al.6 citations
Neurofeedback (NF), a form of biofeedback, is used to enhance the self-regulation of brain functions by assessing brain activity and delivering feedback signals to ameliorate emotional attributes, cognitive functions, and behaviors. Despite the potential role of NF in substance use disorder (SUD) treatment, a number of gaps such as variations in NF methods persist. This study aims to address...
Subanesthetic-dose ketamine has recently been reported to improve hedonic pleasures associated with social interactions and altruism in individuals with treatment-resistant depression. However, whether ketamine-among other glutamate receptor modulators-also improves empathy and/or prosocial behavior in humans remains unknown. Under a framework grounded in neurobiology that proposes that...
Mindfulness based interventions (MBIs) are increasingly recognised for their efficacy in treating depressive disorders. Depressive symptoms are prevalent across various disorders and can significantly impact outcomes, therefore being an important transdiagnostic target. Multiple randomized controlled Trials (RCTs) have explored this question in discrete disorders; however, evidence has never...
Opioid-related overdose deaths have reached record high levels, and novel treatments for opioid use disorder (OUD) are needed. The three United States Food and Drug Administration (FDA)-approved medications for OUD function primarily at the mu-opioid receptor. While these remain the gold-standard treatment for OUD, they have shortcomings and treatment options separate from the opioid receptor...
Assessment measures for suicidal behavior range from depression scales to longer suicide-specific instruments. In this review, we systematically summarize and discuss the currently used instruments for assessing suicidal behavior in the context of ketamine and its enantiomers. We searched Medline/PubMed, Embase, and PsycINFO databases for ketamine (and its enantiomers) human studies exploring...
Psychedelics have re-emerged as promising treatments for mood disorders. The current model provides a moderate-to-high dose of a psychedelic agent (e.g., psilocybin) to reliably induce an altered state of consciousness. Unfortunately, the hallucinatory effects limit the treatment's potential scalability given patients' vulnerability and extensive monitoring costs, leading to growing interest in...
Previous studies have shown patient preference can have large effects on treatment adherence and patient satisfaction. However, the direct effects of matching treatment with patient preference on efficacy and safety outcomes remain unclear. We aimed to evaluate the effects of patient preference and preference-matching on efficacy, adverse events, and adherence to electroconvulsive therapy (ECT)...
Epidemiological data have provided evidence that psychotic-like experiences (PLEs) occur in the general population without clinical impairment. According to the psychosis continuum hypothesis, PLEs are subject to multiple risk factors. This review synthesizes current research on biological, substance use-related, and environmental risk factors for PLEs in non-clinical populations....
A lack of diverse and representative participant samples in mental health intervention research perpetuates mental health disparities. This issue has become a salient concern in studies of psychedelic-assisted psychotherapy (PAT), which is emerging as a promising mental health intervention. This systematic review evaluates the reporting, representation, and analysis of participant...
Accumulating evidence supports the efficacy of (es)ketamine in the treatment of major depressive disorder (MDD), particularly treatment-resistant depression (TRD). Yet around 50% of the individuals with TRD do not respond to (es)ketamine. Elucidating predictors of response and remission could improve treatment outcomes at the individual level by defining subpopulations that are most likely to...
Ketamine is a dissociative drug used for the treatment of depression. However, the neurofunctional mechanism underlying the antidepressant effect of ketamine remains unknown. According to previous research, low-dose ketamine affects large-scale brain networks, including default-mode and salient networks. A total of 43 patients with treatment-resistant depression (TRD) and suicidal ideation (SI)...
Selecting the optimal dose of psilocybin for treating Major Depressive Disorder (MDD) and Treatment-Resistant Depression (TRD) is crucial for clinical development and regulatory approval. This meta-analysis evaluates psilocybin's efficacy and safety in treating MDD to determine the optimal dose and timing for clinical trials. A systematic review and Dose-Response Network Meta-Analysis (NMA) of...
Ketamine and its derivates (e.g. esketamine) are increasingly used in clinical settings for treatment-resistant depression (TRD). Ketamine can give rise to acute, cumulative and longer-term side effects (SEs) across a treatment course. The Ketamine Side Effect Tool (KSET) examines adverse effects though its length has affected feasibility for use in clinical settings. To estimate the frequency...
• A 60-year-old man with recurrent depression and history of delusions died after psilocybin-assisted therapy. • Psilocybin-triggered delusions and emotional dysregulation may have contributed. • Weak therapeutic alliance hindered assessment of patient's internal state. • Delusional symptoms may contraindicate psychedelic interventions. • This case emphasizes the need for thorough assessment...
Suicidal ideation is a significant symptom associated with mood disorders. Ketamine is an emerging treatment with rapid and robust antidepressant and antisuicidal effects observed in clinical trial populations. Herein we assessed the real-world effectiveness of ketamine in ameliorating suicidality. A retroactive chart analysis of 96 adult TRD patients that received treatment in a private...
Racemic ketamine intravenous treatments (KIT) are widely used in community clinics for treatment resistant depression (TRD), but we lack studies on symptom improvement during standardized delivery to clinically complex patients with TRD. We aimed to assess depression symptom change for patients receiving standardized KIT for TRD in a large integrated health care delivery system relative to...